All In Biotech

BLA 761363 · Merck Sharp Dohme

Winrevair

Sotatercept-Csrk · Injection

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Mar 26, 2024: To treat pulmonary arterial hypertension

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Mar 26, 2024

Approved uses

3

Original approval plus efficacy supplements

Registered trials

40

6 Phase 3, 8 recruiting

FAERS reports

6,188

3,495 serious, 286 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 21, 2026.

WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death [see Clinical Studies (14.1) ] . WINREVAIR is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death. ( 1 )

Mechanism: Sotatercept-csrk, a recombinant activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, is an activin signaling inhibitor that binds to activin A and other TGF- β superfamily ligands. As a result, sotatercept-csrk improves the balance between the pro-proliferative (ActRIIA/Smad2/3-mediated) and anti-proliferative (BMPRII/Smad1/5/8-mediated) signaling to modulate vascular proliferation. In rat models of PAH, a sotatercept-csrk analog reduced inflammation and inhibited proliferation of endothelial and smooth muscle cells in diseased vasculature. These cellular changes were associated with...

Therapeutic areas: Cardiovascular and metabolic · Respiratory

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 21, 2026 Supplement 12 · Efficacy OrphanLetterLabel
  • Oct 24, 2025 Supplement 7 · Efficacy · priority review OrphanLetter
  • Mar 26, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • WINREVAIR · SOTATERCEPT-CSRK 60MG · INJECTABLE, INJECTION · Prescription
  • WINREVAIR · SOTATERCEPT-CSRK 45MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sotatercept" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache826
  • dyspnoea698
  • diarrhoea639
  • fatigue548
  • epistaxis537
  • nausea507
  • dizziness504
  • haemoglobin increased315
  • cough275
  • dyspnoea exertional274
  • vomiting256
  • product dose omission issue253

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20212
20224
202340
2024782
20252,268
20263,092

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Winrevair (Sotatercept-Csrk)

2024 spending

$178M

Beneficiaries

1,923

10,663 claims

Per beneficiary

$92,367

$16,651.03 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$177,621,008

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 27 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.